NCT03358693Recruiting
Molecular Signatures in Inflammatory Skin Disease
Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders
Source: ClinicalTrials.gov · Last updated 22 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 4 Nov 2017
- Start date
- 20 Jan 2017
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Prof. Dr. Stephan Weidinger
- Diseases
- Atopic dermatitis (eczema), Psoriasis
- NCT number
- NCT03358693
What you commit to
- Study type: Observational
- Planned participants: 300
- From 20 Jan 2017 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit.
- Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.
Other
- Subject is unable to provide written informed consent or comply with the protocol.
Who the study is looking for
- Ability to provide written informed consent and comply with the protocol
- Dermatologist-diagnosed chronic inflammatory skin disease
- Subject receives systemic therapy within routine care (in-label use of biologics)
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel Coordinator of this site? Confirm its status | Kiel | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.